Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 8/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 8/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549638 | 0.83 | KDM4E (0.53) | TP53MAPTTHRBFNTAFNTB | |
| SCHEMBL17339106 | 0.76 | FNTA (0.60) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL29412239 | 0.76 | MAPT (0.68) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL4705312 | 0.75 | FNTA (0.55) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL28448668 | 0.74 | MAPT (0.48) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL18555742 | 0.72 | GRIN2B (0.35) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL17339164 | 0.72 | MAPT (0.46) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL9531095 | 0.70 | FNTA (0.69) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL17339148 | 0.70 | ALDH1A1 (0.61) | TP53MAPTTHRBBAZ2BBAZ2A | |
| SCHEMBL12394725 | 0.68 | FNTA (0.54) | TP53MAPTTHRBBAZ2BBAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10092584-B2 | Compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035360-A1 | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092584-B2 | Compounds for the treatment of medical disorders | CFD, TFPI, CFH | TP53 4444/4885MAPT 2726/4885THRB 2784/4885 |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | TP53 4444/4885MAPT 2726/4885THRB 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.